We need better ways to find the dangerous prostate cancers early, avoid treating harmless ones, and figure out who really needs testing based on their personal risk.
Scientific Claim
There is consensus that future research must prioritize identifying aggressive prostate cancers currently missed, reducing harms from overdiagnosis, and developing validated risk-stratification tools for men undergoing PSA testing.
Original Statement
“Future research should prioritise discovery and validation of pathways that: ○ find aggressive cancers that are currently being missed; ○ further reduce harms (unnecessary biopsies and detection of clinically insignificant disease) in men who undergo PSA testing through informed choice; and ○ allow for better risk stratification of men who undergo PSA testing through informed choice”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
The claim accurately reports the panel’s agreed-upon research priorities without implying these are proven solutions. The language reflects expert opinion on knowledge gaps, consistent with the study’s design and purpose.
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Randomized Controlled TrialLevel 1bWhether a risk-stratified screening algorithm (combining PSA, MRI, genetics, family history) improves detection of aggressive cancer and reduces overdiagnosis compared to age-based testing.
Whether a risk-stratified screening algorithm (combining PSA, MRI, genetics, family history) improves detection of aggressive cancer and reduces overdiagnosis compared to age-based testing.
What This Would Prove
Whether a risk-stratified screening algorithm (combining PSA, MRI, genetics, family history) improves detection of aggressive cancer and reduces overdiagnosis compared to age-based testing.
Ideal Study Design
A multicenter RCT of 15,000 asymptomatic men aged 50–70 randomized to risk-stratified screening (PSA + polygenic risk score + mpMRI if high risk) vs. standard age-based PSA testing, with primary outcome: proportion of Gleason ≥7 cancers detected and Gleason 6 cancers overdiagnosed at 5 years.
Limitation: Does not assess long-term mortality or cost-effectiveness.
Prospective Cohort StudyLevel 2bThe incidence of aggressive prostate cancer missed by current PSA/MRI pathways in high-risk populations.
The incidence of aggressive prostate cancer missed by current PSA/MRI pathways in high-risk populations.
What This Would Prove
The incidence of aggressive prostate cancer missed by current PSA/MRI pathways in high-risk populations.
Ideal Study Design
A prospective cohort of 5,000 men aged 45–70 with high-risk features (Black ethnicity, BRCA2, family history) undergoing annual PSA and mpMRI, with biopsy only if MRI positive; those with negative MRI but later metastatic cancer identified will define missed aggressive cases.
Limitation: Cannot determine if earlier detection would improve survival.
Prospective Cohort StudyLevel 2bThe rate of unnecessary biopsies and overtreatment in men with low-risk PSA elevations under current practice.
The rate of unnecessary biopsies and overtreatment in men with low-risk PSA elevations under current practice.
What This Would Prove
The rate of unnecessary biopsies and overtreatment in men with low-risk PSA elevations under current practice.
Ideal Study Design
A national cohort of 20,000 men with PSA 3–10 ng/mL undergoing biopsy, with tissue analyzed for genomic markers of aggressiveness; primary outcome: proportion of biopsies revealing Gleason 6 cancer with low-risk genomic profile, secondary: treatment initiation within 1 year.
Limitation: Does not test interventions to reduce harm—only measures current burden.
Evidence from Studies
Supporting (1)
This study gathered doctors and patients to agree on the best way to use the PSA blood test, and they all said we need to do better at finding dangerous prostate cancers early and avoiding unnecessary tests — which is exactly what the claim says.